EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)VergleichsstudieMultizentrische Studie

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU)

Brigitta G Baumert iD, Monika E Hegi iD, Martin J van den Bent iD, Andreas von Deimling, Thierry Gorlia, Khê Hoang-Xuan, Alba A Brandes, Paul Sargos iD, Martin J B Taphoorn iD, Elodie Vauleon, Claire Philips iD, Johan M Kros iD und 23 weitere

Journal of Clinical Oncology · 10.10.2026 · 44 (29) · 2800-2810

DOI: 10.1200/jco-25-02735 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.10.2026. Verfasst von Brigitta G Baumert und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy, Haaglanden Medisch Centrum, The Hague, the Netherlands. Hauptthemen laut MEDLINE: Temozolomide, Glioma, Brain Neoplasms, Antineoplastic Agents, Alkylating. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Prognosis in low-grade gliomas (LGGs) remains highly variable, and treatment-related late toxicity is a concern. This trial was comparing single-modality therapies in patients who often survive for years or decades and investigating differential responses according to molecular markers. METHODS Four hundred seventy-eight patients with clinical high-risk LGG (WHO grade 2) were randomly assigned to standard radiotherapy (RT; 28 × 1.8 Gy) or dose-dense temozolomide (TMZ; 75 mg/m 2 once daily × 21/28 days, up to 12 cycles). RESULTS There was no significant difference in progression-free survival or overall survival (OS) between study arms. Analyzable tumor tissue in 73% (351/478) of patients allowed for post hoc reclassification according to the 2021 WHO pathologic criteria. In astrocytoma, IDHmt/1p/19q noncodeleted (n = 178), median OS was similar, 6.6-6.7 years irrespective of arm (0.67-1.44, P = .93). In oligodendroglioma, IDHmt/1p/19q codeleted (n = 109), median OS was 12.9 years (9.4-not reached) with RT and 14.9 years (10.1-number of events not reached) with TMZ (hazard ratio [HR], 0.88 [0.52-1.49], P = .63). In 64 tumors without isocitrate dehydrogenase (IDH) mutations, survival favored the TMZ arm: OS 2.5 (1.8-3.3) versus 4.7 (2.2-7.2) years (HR, 0.47 [0.27-0.82], P = .0068). Patients age 40 years and older fared better than patients younger than 40 years, challenging the current notion of age alone as a negative prognostic factor. CONCLUSION The assigned initial treatment modality did not affect progression-free survival or OS, regardless of the molecular subtype. Combined-modality therapy was not tested in this trial but has since become a standard of care for IDH-mutant astrocytoma. With emerging novel therapeutic options, rational treatment strategies tailored at the individual clinical and pathologic recurrence risk profiles will be needed. The validity of an age cutoff as prognostic factor is challenged when tumors are molecularly classified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideGliomaBrain NeoplasmsAntineoplastic Agents, AlkylatingHumansFemaleMiddle AgedAdultMaleAgedNeoplasm GradingYoung AdultAdolescent

Substanzen

TemozolomideAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Department of Radiotherapy, Haaglanden Medisch Centrum, The Hague, the Netherlands.
  • Department of Radiation-Oncology (MAASTRO), Maastricht University Medical Center (MUMC) and GROW (School for Oncology), Maastricht, the Netherlands.
  • Neuroscience Research Center and Service of Neurosurgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Departments of Oncology and Clinical Neurosciences, L. Lundin and Family Brain Tumor Research Center, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Erasmus MC University MC Cancer Center, Rotterdam, the Netherlands.
  • Department of Neuropathology, Institute of Pathology, University of Heidelberg, INF 224, and CCU Neuropathology German Cancer Research Center (DKFZ), Heidelberg, Germany.

ORCID-Profile: Brigitta G Baumert, Monika E Hegi, Martin J van den Bent, Paul Sargos, Martin J B Taphoorn, Claire Philips, Johan M Kros, Pierre Bady, Wolfgang Wick, Jacoline E Bromberg, Jaap C Reijneveld, Olivier Chinot, Carmen Balana, Ana Luisa Silva Azevedo, Anna Berghoff, Michael Weller, Warren P Mason, Roger Stupp

Zitieren

APA

Baumert, B. G., Hegi, M. E., van den Bent, M. J., von Deimling, A., Gorlia, T., Hoang-Xuan, K., Brandes, A. A., Sargos, P., Taphoorn, M. J. B., Vauleon, E., Philips, C., Kros, J. M., Bady, P., Wick, W., Enting, R., Reni, M., Thiessen, B., Dhermain, F., Bromberg, J. E., …, & Stupp, R. (2026). Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU). Journal of Clinical Oncology, 44(29), 2800-2810. https://doi.org/10.1200/jco-25-02735

Vancouver

Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, et al. Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU). Journal of Clinical Oncology. 2026;44(29):2800-2810. doi:10.1200/jco-25-02735

BibTeX
@article{Baumert2026,
  author = {Baumert, Brigitta G and Hegi, Monika E and van den Bent, Martin J and von Deimling, Andreas and Gorlia, Thierry and Hoang-Xuan, Khê and Brandes, Alba A and Sargos, Paul and Taphoorn, Martin J B and Vauleon, Elodie and Philips, Claire and Kros, Johan M and Bady, Pierre and Wick, Wolfgang and Enting, Roelien and Reni, Michele and Thiessen, Brian and Dhermain, Frédéric and Bromberg, Jacoline E and Jacob, Julian and Reijneveld, Jaap C and Chinot, Olivier and Gijtenbeek, Johanna M M and Rossiter, John P and Balana, Carmen and Azevedo, Ana Luisa Silva and Clement, Paul M and Berghoff, Anna and Tzuk-Shina, Tzahala and Weller, Michael and Nordal, Robert A and Rees, Jeremy and Lacombe, Denis A and Mason, Warren P and Stupp, Roger},
  title = {Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU)},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {29},
  pages = {2800--2810},
  doi = {10.1200/jco-25-02735}
}
Kostenlos starten →